
## Simon R Lenton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5752479/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology, 2016, 54, 1-13.	0.8	307
2	Patterns of synthetic cannabinoid use in <scp>A</scp> ustralia. Drug and Alcohol Review, 2013, 32, 141-146.	1.1	202
3	The definition of harm reduction. Drug and Alcohol Review, 1998, 17, 213-220.	1.1	140
4	Hidden Populations, Online Purposive Sampling, and External Validity. Field Methods, 2015, 27, 3-21.	0.5	104
5	Constructive activism in the dark web: cryptomarkets and illicit drugs in the digital â€~demimonde'. Information, Communication and Society, 2016, 19, 111-126.	2.6	99
6	The Australian drug harms ranking study. Journal of Psychopharmacology, 2019, 33, 759-768.	2.0	91
7	Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction, 1997, 92, 1327-1337.	1.7	88
8	â€~What if you live on top of a bakery and you like cakes?'—Drug use and harm trajectories before, during and after the emergence of Silk Road. International Journal of Drug Policy, 2016, 35, 50-57.	1.6	83
9	Polydrug use at raves by a Western Australian sample. Drug and Alcohol Review, 1997, 16, 227-234.	1.1	73
10	The rise of new psychoactive substance use in Australia. Drug Testing and Analysis, 2014, 6, 846-849.	1.6	70
11	Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. International Journal of Drug Policy, 2016, 27, 1-12.	1.6	63
12	Pot, politics and the press-reflections on cannabis law reform in Western Australia. Drug and Alcohol Review, 2004, 23, 223-233.	1.1	56
13	Lessons from conducting trans-national Internet-mediated participatory research with hidden populations of cannabis cultivators. International Journal of Drug Policy, 2015, 26, 238-249.	1.6	54
14	Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose?. Medical Journal of Australia, 2000, 173, 260-263.	0.8	53
15	The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug and Alcohol Dependence, 2013, 132, 541-546.	1.6	49
16	Infringement versus conviction: the social impact of a minor cannabis offence in South Australia and Western Australia. Drug and Alcohol Review, 2000, 19, 257-264.	1.1	47
17	New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015. Drug and Alcohol Dependence, 2016, 161, 110-118.	1.6	46
18	Characterising dark net marketplace purchasers in a sample of regular psychostimulant users. International Journal of Drug Policy, 2016, 35, 32-37.	1.6	40

#	Article	IF	CITATIONS
19	Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries. International Journal of Drug Policy, 2015, 26, 226-237.	1.6	39
20	An overview of takeâ€home naloxone programs in Australia. Drug and Alcohol Review, 2018, 37, 440-449.	1.1	37
21	Internet content regulation, public drug websites and the growth in hidden Internet services. Drugs: Education, Prevention and Policy, 2013, 20, 195-202.	0.8	36
22	Into the void: Regulating pesticide use in Colorado's commercial cannabis markets. International Journal of Drug Policy, 2017, 42, 86-96.	1.6	36
23	Motivations for new psychoactive substance use among regular psychostimulant users in Australia. International Journal of Drug Policy, 2017, 43, 23-32.	1.6	36
24	"PMA Sounds Fun― Negotiating Drug Discourses Online. Substance Use and Misuse, 2014, 49, 987-998.	0.7	35
25	Findings and lessons learnt from implementing Australia's first health service based takeâ€home naloxone program. Drug and Alcohol Review, 2018, 37, 464-471.	1.1	34
26	Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond. Drug and Alcohol Review, 2015, 34, 404-411.	1.1	31
27	Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries. International Journal of Drug Policy, 2015, 26, 250-256.	1.6	31
28	Legal cannabis industry adopting strategies of the tobacco industry. Drug and Alcohol Review, 2016, 35, 511-513.	1.1	31
29	Changes in illicit drug use and markets with the COVIDâ€19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20. Addiction, 2022, 117, 182-194.	1.7	31
30	Cannabis and harm reduction. Drug and Alcohol Review, 2000, 19, 101-112.	1.1	30
31	Surveying alcohol and other drug use through telephone sampling: a comparison of landline and mobile phone samples. BMC Medical Research Methodology, 2013, 13, 41.	1.4	30
32	Raves, drugs, dealing and driving: qualitative data from a West Australian sample. Drug and Alcohol Review, 1999, 18, 153-161.	1.1	28
33	Australia reschedules naloxone for opioid overdose. Medical Journal of Australia, 2016, 204, 146-147.	0.8	28
34	The challenges and benefits of analyzing feedback comments in surveys: Lessons from a cross-national online survey of small-scale cannabis growers. Methodological Innovations, 2019, 12, 205979911982560.	0.5	28
35	Understanding global patterns of domestic cannabis cultivation. Drugs and Alcohol Today, 2012, 12, 213-221.	0.3	27
36	Does training people to administer takeâ€home naloxone increase their knowledge? Evidence from Australian programs. Drug and Alcohol Review, 2018, 37, 472-479.	1.1	27

#	Article	IF	CITATIONS
37	Representativeness of online purposive sampling with Australian cannabis cultivators. International Journal of Drug Policy, 2015, 26, 323-326.	1.6	25
38	The contribution of music vs instructions in the Musical Mood Induction Procedure. Behaviour Research and Therapy, 1991, 29, 623-625.	1.6	24
39	Clarifying â€ <sup>~</sup> harm reduction'?. Drug and Alcohol Review, 1996, 15, 411-413.	1.1	24
40	Cannabis policy and the burden of proof: is it now beyond reasonable doubt that cannabis prohibition is not working?. Drug and Alcohol Review, 2000, 19, 95-100.	1.1	24
41	Frequent experience of discrimination among people who inject drugs: Links with health and wellbeing. Drug and Alcohol Dependence, 2018, 190, 188-194.	1.6	24
42	Cops, drugs and the community: establishing consultative harm reduction structures in two Western Australian locations. International Journal of Drug Policy, 2002, 13, 185-192.	1.6	23
43	Naloxone for administration by peers in cases of heroin overdose. Medical Journal of Australia, 2009, 191, 469-469.	0.8	23
44	Assessing causality in drug policy analyses: How useful are the Bradford Hill criteria in analysing takeâ€home naloxone programs?. Drug and Alcohol Review, 2018, 37, 499-501.	1.1	22
45	Drug detection dogs at Australian outdoor music festivals: Deterrent, detection and iatrogenic effects. International Journal of Drug Policy, 2018, 60, 89-95.	1.6	22
46	Citizens who inject drugs: the â€~Fitpack' study. International Journal of Drug Policy, 2000, 11, 285-297.	1.6	21
47	Affective disorders and anxiety disorders predict the risk of drug harmful use and dependence. Addiction, 2011, 106, 1126-1134.	1.7	21
48	Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand. International Journal of Drug Policy, 2022, 105, 103712.	1.6	21
49	SPECIAL SECTION: EVALUATION OF THE WESTERN AUSTRALIAN CANNABIS INFRINGEMENT NOTICE SCHEME-PHASE 1: Community attitudes towards cannabis law and the proposed Cannabis Infringement Notice scheme in Western Australia. Drug and Alcohol Review, 2005, 24, 301-309.	1.1	18
50	The burgeoning recognition and accommodation of the social supply of drugs in international criminal justice systems: An eleven-nation comparative overview. International Journal of Drug Policy, 2018, 58, 93-103.	1.6	18
51	Harm reduction in Australia: has it worked? A review. Drug and Alcohol Review, 1995, 14, 291-304.	1.1	17
52	Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. Drug and Alcohol Review, 2009, 28, 583-585.	1.1	17
53	Pre-Drinking Behavior of Young Heavy Drinkers. Substance Use and Misuse, 2016, 51, 1297-1306.	0.7	17
54	Trends in reports of driving following illicit drug consumption among regular drug users in Australia, 2007–2013: Has random roadside drug testing had a deterrent effect?. Accident Analysis and Prevention, 2017, 104, 146-155.	3.0	17

#	Article	IF	CITATIONS
55	Youth perceptions of alcohol advertising: are current advertising regulations working?. Australian and New Zealand Journal of Public Health, 2018, 42, 234-239.	0.8	16
56	Knowledge of naloxone and takeâ€home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities. Drug and Alcohol Review, 2018, 37, 457-463.	1.1	16
57	Arrest, Court and Social Impacts of Conviction for a Minor Cannabis Offense under Strict Prohibition. Contemporary Drug Problems, 2000, 27, 805-833.	0.7	15
58	Attitudes of cannabis growers to regulation of cannabis cultivation under a non-prohibition cannabis model. International Journal of Drug Policy, 2015, 26, 257-266.	1.6	15
59	Most recent risky drinking session with Australian teenagers. Australian and New Zealand Journal of Public Health, 2017, 41, 105-110.	0.8	15
60	Double dropping down under: Correlates of simultaneous consumption of two ecstasy pills in a sample of Australian outdoor music festival attendees. Drug and Alcohol Review, 2018, 37, 851-855.	1.1	15
61	Alcoholâ€related problems in a general hospital and a general practice: screening and the preventive paradox. Medical Journal of Australia, 1988, 149, 355-360.	0.8	15
62	Dope busts in the West: minor cannabis offences in the Western Australian criminal justice system. Drug and Alcohol Review, 1996, 15, 335-341.	1.1	14
63	Cannabis law reform in Western Australia: an opportunity to test theories of marginal deterrence and legitimacy*. Drug and Alcohol Review, 2005, 24, 321-330.	1.1	14
64	Recidivist drink drivers' self-reported reasons for driving whilst unlicensed—A qualitative analysis. Accident Analysis and Prevention, 2010, 42, 637-644.	3.0	14
65	Growing practices and the use of potentially harmful chemical additives among a sample of small-scale cannabis growers in three countries. Drug and Alcohol Dependence, 2018, 192, 250-256.	1.6	14
66	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. Research in Social and Administrative Pharmacy, 2019, 15, 1047-1055.	1.5	13
67	Examining the blurred boundaries between medical and recreational cannabis – results from an international study of small-scale cannabis cultivators. Drugs: Education, Prevention and Policy, 2019, 26, 250-258.	0.8	13
68	Patterns of drug use by participants in the Western Australian methadone program, 1984â€1991. Medical Journal of Australia, 1993, 159, 373-376.	0.8	13
69	Community Attitudes to Cannabis Use in Western Australia. Journal of Drug Issues, 1996, 26, 783-804.	0.6	12
70	Designing, implementing and evaluating the overdose response with takeâ€home naloxone model of care: An evaluation of client outcomes and perspectives. Drug and Alcohol Review, 2020, 39, 55-65.	1.1	12
71	Alcohol policy impact on young risky drinkers and their support for proposed measures. Australian and New Zealand Journal of Public Health, 2015, 39, 129-134.	0.8	11
72	A trial of naloxone for peer administration has merit, but will the lawyers let it happen?. Drug and Alcohol Review, 2000, 19, 365-369.	1.1	10

#	Article	IF	CITATIONS
73	Social capital and cannabis supply. Journal of Sociology, 2017, 53, 382-397.	0.9	10
74	Threat or Opportunity? Secondary Exchange in a Setting With Widespread Availability of Needles. Substance Use and Misuse, 2006, 41, 845-864.	0.7	9
75	Evidence of increasing age of onset of cannabis use among younger Australians. Addiction, 2012, 107, 650-657.	1.7	9
76	A tale of CIN—the Cannabis Infringement Notice scheme in Western Australia. Addiction, 2010, 105, 808-816.	1.7	8
77	Does Availability of Illicit Drugs Mediate the Association between Mental Illness and Substance Use?. Substance Use and Misuse, 2011, 46, 1304-1308.	0.7	8
78	New regulated markets for recreational cannabis: public health or private profit?. Addiction, 2014, 109, 354-355.	1.7	8
79	Expected impacts of the Cannabis Infringement Notice scheme in Western Australia on regular users and their involvement in the cannabis market. Drug and Alcohol Review, 2005, 24, 311-319.	1.1	7
80	Public awareness, knowledge and attitudes regarding the CEN system in South Australia. Drug and Alcohol Review, 2000, 19, 271-280.	1.1	6
81	Potential impacts on the incidence of fatal heroin-related overdose in Western Australia: a time-series analysis. Drug and Alcohol Review, 2002, 21, 321-327.	1.1	6
82	Online alcohol interventions, sexual violence and intimate partner violence: A systematic review. Internet Interventions, 2015, 2, 152-160.	1.4	6
83	Re-thinking pre-drinking: Implications from a sample of teenagers who drink in private settings. International Journal of Drug Policy, 2018, 52, 20-24.	1.6	6
84	Insomnia and Regulation of Sleep-Wake Cycle With Drugs Among Adolescent Risky Drinkers. Journal of Clinical Sleep Medicine, 2018, 14, 1529-1537.	1.4	6
85	Alcohol supply as a favour for a friend: Scenarios of alcohol supply to younger friends and siblings. Health Promotion Journal of Australia, 2020, 31, 112-120.	0.6	6
86	Practical lessons learned from the first years of the regulated recreational cannabis market in Colorado. , 2020, , 39-61.		6
87	Drug policing down under: An investigation of panic consumption, internal concealment and the use of drug amnesty bins among a sample of Australian festivalgoers. International Journal of Drug Policy, 2022, 106, 103769.	1.6	6
88	A framework for prevention. Drug and Alcohol Review, 2005, 24, 49-55.	1.1	5
89	Global patterns of domestic cannabis cultivation: sample characteristics and patterns of growing across eleven countries. , 2016, , 163-196.		5
90	Cannabis and youth protection in Colorado's commercial adult-use market: A qualitative investigation. International Journal of Drug Policy, 2019, 74, 116-126.	1.6	5

#	Article	IF	CITATIONS
91	From eye rolls to punches: experiences of harm from others' drinking among risky-drinking adolescents across Australia. Public Health Research and Practice, 2019, 29, .	0.7	5
92	The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioidâ€related deaths: findings from a modelling study. Addiction, 2022, 117, 1009-1019.	1.7	5
93	Laws applying to minor cannabis offences in Australia and their evaluation. International Journal of Drug Policy, 1999, 10, 299-303.	1.6	4
94	Policy from a harm reduction perspective. Current Opinion in Psychiatry, 2003, 16, 271-277.	3.1	4
95	Evaluation of the Western Australian Cannabis Infringement Notice scheme-an overview. Drug and Alcohol Review, 2005, 24, 297-299.	1.1	4
96	Research regulation by omission and by publication. International Journal of Drug Policy, 2006, 17, 244-245.	1.6	4
97	Characteristics of cannabis cultivation in New Zealand and Israel. Drugs and Alcohol Today, 2018, 18, 90-98.	0.3	3
98	Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia. Drug and Alcohol Review, 2020, 39, 83-92.	1.1	3
99	Commentary. Drug and Alcohol Dependence, 1994, 35, 175.	1.6	2
100	Title is missing!. Current Opinion in Psychiatry, 2003, 16, 271-277.	3.1	2
101	Enhancing clinical research with alcohol, tobacco and cannabis problems and dependence. Drug and Alcohol Review, 2010, 29, 483-490.	1.1	2
102	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. Addiction, 2011, 106, 1192-1193.	1.7	2
103	The social supply of cannabis in Australia: Definitional challenges and regulatory possibilities. , 2016, , 29-46.		2
104	On sentinel samples, sales data and potency. Addiction, 2017, 112, 1137-1138.	1.7	2
105	Takeâ€home naloxone in Australia and beyond. Drug and Alcohol Review, 2018, 37, 437-439.	1.1	2
106	Study drug use among university students in Western Australia: Results of a web survey and their policy and practice implications. Drug and Alcohol Review, 2021, 40, 530-539.	1.1	2
107	Regulating cannabis retail for public health over private profit. Addiction, 2021, 116, 233-235.	1.7	2
108	Hepatitis B Infection — a proxy measure of risk factors for HIV infection in IVDUs?. Medical Journal of Australia, 1990, 153, 434-435.	0.8	2

#	Article	IF	CITATIONS
109	Expected impacts of the Cannabis Infringement Notice scheme in Western Australia on attitudes and drug use of school children. Drug and Alcohol Review, 2005, 24, 337-345.	1.1	1
110	[Commentary] CASE FOR PEER NALOXONE FURTHER STRENGTHENED. Addiction, 2008, 103, 1658-1659.	1.7	1
111	Self-reported recent testing and diagnosis for sexually transmitted infections among regular ecstasy users in Australia, 2011-2012. Drug and Alcohol Review, 2014, 33, 211-214.	1.1	1
112	The Overdose Response with Take Home Naloxone ( <scp>ORTHN</scp> ) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review, 2022, 41, 1085-1094.	1.1	1
113	Controlled Drinking for Whom?. Australian Drug and Alcohol Review, 1987, 6, 131-136.	0.2	0
114	Multivariate Data and Type I Error. Addiction, 1989, 84, 441-441.	1.7	0
115	Commentary on <scp>W</scp> illiams <i>et al</i> . (2014): Family matters—new resources for managing opioid overdose with takeâ€home naloxone. Addiction, 2014, 109, 260-261.	1.7	0
116	Social Bias in the Policing of Illicit Drug Users in the UK and Australia: Findings from a Self-Report Study. SSRN Electronic Journal, 2015, , .	0.4	0
117	Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers?. Drugs and Alcohol Today, 2019, 19, 251-256.	0.3	0
118	Safety first: Beliefs of older peers supplying alcohol to underage friends. Health Promotion Journal of Australia, 2020, 32, 407-415.	0.6	0
119	The Potential Effects of Policy Changes on Drug Markets in the UK and Australia: Estimates from a Survey of Drug Users. SSRN Electronic Journal, 0, , .	0.4	Ο